Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24793816

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2014 Jun
First author
Krop IE

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Jun;15(7):668-9. doi: 10.1016/S1470-2045(14)70192-5.
    note
    Source null
    related pmid
    24793817
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2014 Jul;11(7):379. doi: 10.1038/nrclinonc.2014.99.
    note
    Source null
    related pmid
    24913372
    relationship
    Comment in

Authors and identifiers

  1. name
    Krop IE
    type
    Author
  2. name
    Kim SB
    type
    Author
  3. name
    González-Martín A
    type
    Author
  4. name
    LoRusso PM
    type
    Author
  5. name
    Ferrero JM
    type
    Author
  6. name
    Smitt M
    type
    Author
  7. name
    Yu R
    type
    Author
  8. name
    Leung AC
    type
    Author
  9. name
    Wildiers H
    type
    Author
  10. name
    TH3RESA study collaborators
    type
    CollectiveName
Complete bibliographic record and source provenance
authors
  1. name
    Krop IE
    type
    Author
  2. name
    Kim SB
    type
    Author
  3. name
    González-Martín A
    type
    Author
  4. name
    LoRusso PM
    type
    Author
  5. name
    Ferrero JM
    type
    Author
  6. name
    Smitt M
    type
    Author
  7. name
    Yu R
    type
    Author
  8. name
    Leung AC
    type
    Author
  9. name
    Wildiers H
    type
    Author
  10. name
    TH3RESA study collaborators
    type
    CollectiveName
bibliography ids
  1. nci-bib-7c3ae732460205aa07bf8aa4
book metadata
content sha256
fe1b6e33c6e589d2e0b675ff3138fff7ebcb7329fc82a84cc01ce7aa512e94a3
document type
citation
dois
  1. 10.1016/S1470-2045(14)70178-0
electronic publication date
display
2014 May 2
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24793816
immutable id
pubmed:24793816@fe1b6e33c6e589d2e0b675ff3138fff7ebcb7329fc82a84cc01ce7aa512e94a3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
689-99
volume
15
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Jun;15(7):668-9. doi: 10.1016/S1470-2045(14)70192-5.
    note
    Source null
    related pmid
    24793817
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2014 Jul;11(7):379. doi: 10.1038/nrclinonc.2014.99.
    note
    Source null
    related pmid
    24913372
    relationship
    Comment in
outcomes validated
false
pmid
24793816
provenance
batch id
063b6c38419f18d4021f
provider
NCBI PubMed ESummary
record sha256
6950e6886000daeac71cba376fbaac149fb30cf9f8d7de9f8ed77b4c66df1957
response sha256
5abcae41e9384a85f92695ef76b244ffd933f07a58a51082c160af8743d196ad
retrieved at
2026-09-09T23:47:02.607425+00:00
publication date
display
2014 Jun
precision
month
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24793816/
title
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice